Every 424B that Axogen Inc (AXGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AXGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AXGN filings page.
Axogen, Inc. (AXGN) is conducting a primary offering of 4,910,000 shares of common stock at a public offering price of $42.50 per share, for gross proceeds of $208.7 million and estimated net proceeds of about $195.5 million after fees and expenses. Underwriters have a 30‑day option to buy up to 736,500 additional shares. Shares outstanding will increase from 53,656,293 as of June 30, 2026 to 58,566,293 (or 59,302,793 if the option is fully exercised). The company plans to use substantially all net proceeds to fund the $200.0 million cash purchase of BioCircuit Technologies, Inc. and related costs, with any remainder for general corporate purposes; if the acquisition is not completed, all proceeds will be used for general corporate purposes. New investors face immediate dilution, as net tangible book value rises from $4.63 to $7.58 per share versus the $42.50 offering price.
Axogen, Inc. is conducting a public offering of 4,000,000 shares of common stock at $31.00 per share, with underwriters holding a 30‑day option to buy up to 600,000 additional shares. The company expects net proceeds of about $115.9 million (or $133.3 million if the option is fully exercised) and plans to use roughly $69.7 million to repay and terminate its Oberland credit facility, with the balance for working capital and capital spending.
Axogen reports preliminary 2025 revenue of about $225.2 million, up roughly 20.2% year over year, and fourth‑quarter revenue of about $59.9 million, up about 21.3%. Gross margin for 2025 and the fourth quarter is expected to be above 74%, including approximately $1.9 million in largely non‑cash one‑time costs tied to FDA approval milestones.
On December 3, 2025, the FDA approved Axogen’s Biologics License Application for Avance, an acellular nerve scaffold for specific sensory, mixed, and motor nerve indications, with certain uses granted under the accelerated approval pathway and subject to a confirmatory post‑marketing study.
Axogen is offering $85 million of common stock in a primary equity raise. The company has also granted underwriters a 30-day option to buy up to an additional $12.75 million of shares. Axogen currently intends to use a significant portion of the net proceeds to make an early payoff of its Oberland credit facility, with a final repayment amount expected to be approximately $69.7 million, which would terminate all obligations under that debt.
Alongside the financing, Axogen outlines strong preliminary 2025 results, with expected revenue of about $59.9 million for the fourth quarter and $225.2 million for the full year, increases of 21.3% and 20.2% versus 2024. Gross margin for 2025 is expected to be above 74%, despite about $1.9 million of one-time costs tied to FDA approval of its Avance biologic. The company ended 2025 with approximately $45.5 million in cash, cash equivalents, restricted cash and investments, up about $6.0 million from a year earlier.
The FDA approved Axogen’s Biologics License Application for Avance in December 2025, granting full approval for certain sensory nerve indications and accelerated approval for longer sensory and mixed and motor nerve repairs, subject to a confirmatory post-marketing study running through 2030 with a final report due in 2031.